IGM Biosciences, Inc. Gains 96.73%

IGM Biosciences, Inc. (IGMS:NASDAQ) shot up at $29.49, representing a gain of 96.7%. The stock got featured on our News Catalysts scanner on Tue, Mar 29, 2022 at 03:14 PM in the 'AGREEMENT' category. From Mon, Mar 14, 2022, the stock recorded 50.00% Up Days and 54.55% Green Days

About IGM Biosciences, Inc. (IGMS:NASDAQ)

IGM Biosciences Inc is a biotechnology company involved in the development of engineered IgM antibodies for the treatment of cancer patients. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.